This study is a prospective, single arm phase II study aimed at patients with locally advanced or metastatic non-small cell lung cancer undergoing second-line or beyond treatment. The aim is to evaluate the bone marrow protective effect of trilaciclib before docetaxel chemotherapy for locally advanced or metastatic NSCLC.
Age ≥ 18 years old, regardless of gender;
At least one measurable lesion that meets the RECIST 1.1 criteria exists;
ECOG PS score 0-2;
Expected survival time ≥ 3 months;
Previously received treatment with docetaxel;
Diagnosed with malignant diseases other than NSCLC within 5 years prior to the first administration (excluding curative basal cell carcinoma, squamous cell carcinoma, and/or excised carcinoma in situ);
Uncontrolled ischemic heart disease or clinically significant congestive heart failure (NYHA class III or IV);
Stroke or cardiovascular events within the first 6 months of enrollment;